Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)? (Cardiovascular Drugs and Therapy, (2018), 32, 6, (633-635), 10.1007/s10557-018-6830-x)

Rosa Ahn, Vinay Prasad

Research output: Contribution to journalComment/debatepeer-review

Abstract

The original version of this article unfortunately contained a mistake. There was a typo in the second sentence of the paragraph under the section Was the Dose of Drugs Fair?; "320 mg twice a day" should read "160mg twice a day". The corrected paragraph is shown below.

Original languageEnglish (US)
Pages (from-to)637
Number of pages1
JournalCardiovascular Drugs and Therapy
Volume32
Issue number6
DOIs
StatePublished - Dec 1 2018

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)? (Cardiovascular Drugs and Therapy, (2018), 32, 6, (633-635), 10.1007/s10557-018-6830-x)'. Together they form a unique fingerprint.

Cite this